Clinical Trials Logo

Filter by:
NCT ID: NCT00743587 Completed - Clinical trials for Osteoarthritis Thumbs

A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if the measurement of pressure pain thresholds, in patients suffering osteoarthritis of the thumb, can be used to assess the activity of potential analgesic agents after a single dose. The study will use agents known to give pain relief in osteoarthritis as positive controls. These agents are: tramadol, naproxen and oxycodone.

NCT ID: NCT00743015 Completed - Migraine Disorders Clinical Trials

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The general aim is to evaluate the relative oral bioavailability of BI 44370 TA tablets during and between migraine attacks as well as Safety, Tolerability and Pharmacokinetic

NCT ID: NCT00742092 Completed - Cystic Fibrosis Clinical Trials

Miglustat in Cystic Fibrosis

Start date: August 2008
Phase: Phase 2
Study type: Interventional

Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period/Two-Treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

NCT ID: NCT00742027 Completed - Clinical trials for Classical Hodgkin's Lymphoma

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Start date: September 16, 2008
Phase: Phase 2
Study type: Interventional

This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.

NCT ID: NCT00741481 Completed - Clinical trials for Colorectal Cancer Metastatic

PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.

earlyPETmCRC
Start date: June 2006
Phase: N/A
Study type: Observational

Study hypothesis : early decrease in fdg-pet measured SUV max after 1 cycle of chemotherapy can accurately predict response of chemotherapy as assessed by conventional radiology after 3 cycles of chemotherapy. FDG-PET imaging will be done at J0 and J14 of a new line of chemotherapy treatment in metastatic colorectal cancer. SUV max will be recorded and delta SUVmax will be compared to the results of conventional radiological evaluation after 3 courses of chemotherapy. Results will also be compared to the time to disease progression.

NCT ID: NCT00740831 Completed - Uterine Myomas Clinical Trials

PGL4001 Versus GnRH-agonist in Uterine Myomas

PEARLII
Start date: August 2008
Phase: Phase 3
Study type: Interventional

This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.

NCT ID: NCT00740194 Completed - Healthy Clinical Trials

Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men

Start date: August 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Aromatase inhibition versus estradiol during 1 week

NCT ID: NCT00740129 Completed - Clinical trials for Paget's Disease of the Bone

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Start date: October 21, 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.

NCT ID: NCT00740103 Completed - Crohn's Disease Clinical Trials

Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

CD05
Start date: December 2002
Phase: Phase 2
Study type: Interventional

CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI).

NCT ID: NCT00739986 Completed - Crohn's Disease Clinical Trials

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

CD04
Start date: October 2002
Phase: Phase 2
Study type: Interventional

Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).